Dermatology

Eblasakimab shows promising itch relief in dupilumab-experienced atopic dermatitis patients, with significant reductions in symptoms observed.

This presentation at ACP Internal Medicine 2024 covered key skills Colven believes internists should know for identification of dermatologic conditions.

These data represent the largest single-center, long-term study on booster vaccines at a public hospital’s dermatology department in Japan.

This analysis compared the efficacy of a 5 mg daily dose of oral minoxidil to topical minoxidil, 5%, among male alopecia patients.

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

This analysis was conducted to address the fact that, while there are various acne specific instruments to assess quality of life domains, none exist to focus on all of the domains.

This study’s investigators point to the necessity of adapting an antibiotic stewardship program for acne treatment, with evaluation being done in dermatology practices to assess performance.

In these data, investigators had investigated the international differences in topical AK medication implementation, including links to countries’ different economic statuses.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

This analysis was conducted to evaluate the burden and disease characteristics of all 3 types of HAE among a set of Canadian patients.

In this review of the top stories in dermatology in March, several were highlighted such as the recent report on benzene in skincare products and the FDA’s approval of spesolimab for generalized pustular psoriasis.

Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.

Dermatology physician assistants are talking about the evolving role of their profession in taking care of patients with plaque psoriasis.

Advances practice providers TJ Chao, MPAS, PA-C and Kristine Kucera, PA-C, MPAS, DHS discuss the recent development in the treatment landscape of plaque psoriasis.

Following this analysis, the conclusions provide more information on the views of potential dermatology patients on the future of their own medical images by artificial intelligence systems.

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.

The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.

In this analysis from the UK, the DDPS led to improved pathway management which also achieved lower service demand and smaller waiting lists for dermatologists.

April W. Armstrong, MD, MPH, shares her experience using oral systemic treatments in clinical practice for the management of plaque psoriasis.

An expert in dermatologic conditions examines laboratory requirements for initiating deucravacitinib in patients with moderate-to-severe plaque psoriasis and the impact of deucravacitinib on the treatment landscape.

These data indicate that, despite the promise held by AI in dermatological care improvement, further evaluation of training, validation, and ethical issues must be done before it is integrated.

These data highlight the risk of anxiety and depression among dermatologists, with notable findings based on gender differences observed among clinicians.

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

The results of this analysis highlight the link between patients’ experiences with pruritus intensity and the mental health difficulties such struggles place on patients.

Isotretinoin was actually linked to a taller adult height among those who took it to treat acne in childhood versus doxycycline, in a new study.

In this AAD 2024 interview, Bunick highlights several new findings on the use of topical isotretinoin for treatment of congenital ichthyosis.

New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.

Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.

Dr April W. Armstrong reviews key findings from the phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials evaluating the use of deucravacitinib for the treatment of plaque psoriasis.